Recently, the prime-time news programs of mainstream media such as Jiangsu Satellite TV and Dragon TV reported on the scientific and technological innovation and clinical significance of Ameile (Ametinib Mesylate Tablets), a Class 1 innovative drug independently developed by Hansoh Pharma.
On April 18, Jiangsu News Watch, a prime-time news program of Jiangsu Satellite TV, aired a special report titled "Recording New Highs in Both Project Quantity and Total Investment, Jiangsu has 447 Key Industrial Investment Projects Under Way in 2020", highlighting the development layout of Hansoh Pharma as well as the excellent efficacy and safety of Ameile.
Caption: Video of report by Jiangsu News Watch of Jiangsu Satellite TV
On April 17, Oriental News, the flagship news program of Dragon TV, reported the approval of Hansoh Pharma's Ameile for marketing under the headline of "First Domestic Third-generation Targeted Drug for Lung Cancer Approved for Marketing, New Choice for Advanced Lung Cancer Patients after Drug Resistance", pointing out that as the first third-generation EGFR targeted drug independently developed in China, Ameile has brought a new choice for long-term and high-quality survival to patients with advanced non-small cell lung cancer (NSCLC).
Caption: Video of report by Oriental News of Dragon TV
On April 17, in the Night Interview program of Shanghai TV's News Channel, Professor Lu Shun, Leading PI of clinical research in Ameile and Director of the Department of Oncology of the Chest Hospital Affiliated to Shanghai Jiao Tong University, shared and affirmed the clinical significance of Ameile and its contribution in solving the drug accessibility problem.
Professor Lu noted, "For advanced NSCLC patients who have developed EGFR T790M mutation that is resistant to EGFR first- or second-generation drugs, the third-generation drug (Ameile) can bring very good efficacy, reducing tumors by half in 60-70% of patients."
Caption: Video of report by Night Interview of Shanghai TV
Wen Wei Po, Liberation Daily, Xinmin Evening News, Shanghai Radio Station and other mainstream media have all reported on Ameile.
Ameile is the world's second third-generation EGFR-TKI innovative drug and the world's first third-generation EGFR-TKI with a median progression-free survival time (MPFS) of more than one year (second-line use). As the third-generation EGFR targeted drug independently developed in China, the approval of Ameile for marketing provides clinicians with a new, highly efficacious, safe and accessible option, and brings the hope for long-term and high-quality survival to more patients with advanced NSCLC.
As a leading innovation-driven enterprise in China, Hansoh Pharma will live up to its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China" by accelerating the pace of scientific and technological innovation, putting patients' benefits always in the first place, and committing itself to meeting the unmet clinical needs.
